Andersson R
Department of Infectious Diseases, Ostra Hospital, Göteborg, Sweden.
J Interferon Cytokine Res. 1995 Oct;15(10):837-8. doi: 10.1089/jir.1995.15.837.
Chronic recurrent multifocal osteomyelitis (CRMO) is a rare disease of unknown etiology characterized by multiple osteomyelitic changes in the predominantly metaphysial regions of long bones. It was first described by Giedon et al. in 1972. Cultures for all known microorganisms are negative. Pain is the most common symptom, and sometimes soft tissue swelling is present. Patients are usually treated with nonsteroidal antiinflammatory drugs (NSAIDs) or corticosteroids and respond, at least partly, to these treatments. CRMO is most commonly seen in children and is in the majority of cases self-limiting but has a protracted course of several years. Some patients have a more prolonged disease period, as in the patient reported here. Treatment with corticosteroids in children has the risk of causing growth retardation as a potential adverse effect, and alternative treatments are of great interest. In the actual paper, a successful treatment with interferon-alpha 2b in a 34-year-old man with CRMO is presented.
慢性复发性多灶性骨髓炎（CRMO）是一种病因不明的罕见疾病，其特征是在长骨主要的干骺端区域出现多处骨髓炎改变。它于1972年由吉登等人首次描述。所有已知微生物的培养结果均为阴性。疼痛是最常见的症状，有时还会出现软组织肿胀。患者通常接受非甾体抗炎药（NSAIDs）或皮质类固醇治疗，并且至少部分患者对这些治疗有反应。CRMO最常见于儿童，大多数病例为自限性，但病程长达数年。一些患者的疾病期更长，如此处报告的患者。儿童使用皮质类固醇治疗有导致生长发育迟缓的潜在不良反应风险，因此替代治疗备受关注。在实际论文中，介绍了一名34岁CRMO男性患者使用干扰素-α 2b成功治疗的病例。
